EBR moves closer to national Medicare coverage for WiSE heart pacing

CMS has proposed national Medicare coverage for EBR Systems’ WiSE cardiac pacing system, potentially replacing case-by-case decisions for eligible Medicare Advantage patients. The proposal remains subject to public comment, a final determination and evidence collection through the proposed WiSE-CHOICE study.

  • Proposed national Medicare coverage across traditional Medicare and Medicare Advantage
  • Coverage would target patients unable to receive conventional CRT or high-risk CRT upgrades
  • Eligible patients would enrol in the proposed WiSE-CHOICE real-world evidence study
  • Public comments close on 18 December 2026, with a final decision expected by 16 February 2027
An image related to EBR Systems Inc A photo of the logo for EBR Systems Add us as a preferred source on Google
Image © middle. Logo © respective owner.

CMS Opens National Coverage Pathway for WiSE

EBR Systems, Inc. (ASX:EBR) has moved closer to a potentially significant commercial milestone after the US Centers for Medicare & Medicaid Services proposed national Medicare coverage for its WiSE System. If finalised, the proposal would extend coverage across both traditional Medicare and Medicare Advantage for eligible patients, giving hospitals and physicians a more predictable reimbursement framework.

The proposal was published on 18 November under CMS’s Transitional Coverage for Emerging Technologies pathway. It is not yet effective: Medicare Advantage coverage remains subject to regional Medicare Administrative Contractor decisions while the proposal proceeds through public comment and final review.

Coverage Targets Patients With Limited CRT Options

CMS’s proposed criteria broadly follow WiSE’s FDA-approved indication. They cover patients whose coronary sinus lead implantation was unsuccessful, or whose implanted lead has been switched off, as well as high-risk upgrades for patients with an existing pacemaker or defibrillator where a standard CRT upgrade is considered inadvisable because of known relative contraindications.

The reimbursement development builds on CMS’s earlier decision to raise Medicare inpatient payment rates for WiSE procedures, with the new rates taking effect from 1 October. That link is not permitted.

EBR’s recent Medicare pricing decision is not valid syntax. Need fix no href. The sentence: "The reimbursement development builds on the higher Medicare reimbursement ..." This is same paragraph, background clause from article. Need use exact marker.

The reimbursement development builds on the higher Medicare reimbursement, which took effect on 1 October. The proposed national framework could address a separate commercial friction point: access to coverage, particularly for Medicare Advantage patients who currently require case-by-case regional approval. The filing does not quantify the potential effect on procedure volumes, revenue or hospital adoption.

WiSE-CHOICE Evidence Requirement Sets Next Test

Coverage under the proposed Coverage with Evidence Development arrangement would come with a condition. Eligible patients would be enrolled in the proposed WiSE-CHOICE study, which would compare real-world outcomes with WiSE against standard treatments and track survival and heart failure hospitalisations for at least 24 months.

That structure gives EBR a route towards broader reimbursement while leaving the company responsible for generating longer-term evidence. Chief executive John McCutcheon called the proposal a milestone for patients unable to receive conventional CRT and said EBR would work with CMS on the final determination and study framework.

Public comments close on 18 December 2026, and CMS is expected to issue its final decision by 16 February 2027. The important variables before then are whether the coverage criteria or study design change, and whether the final policy produces the reimbursement certainty EBR says physicians and hospitals need.

Get ASX:EBR news the moment it breaks

Instant push notifications No waitlist Free
Download on the App Store iPhone & iPad
Get it on Google Play Android
Email alerts

Bottom Line?

The proposal improves EBR’s reimbursement pathway, but the commercial payoff still depends on final coverage, study obligations and the rate at which hospitals adopt WiSE.

Questions in the middle?

  • Will CMS retain the proposed eligibility criteria and WiSE-CHOICE evidence requirements in its final determination?
  • How quickly could national coverage translate into higher WiSE procedure volumes across Medicare Advantage and traditional Medicare?
  • Can EBR convert improved reimbursement access into sustained commercial growth while continuing to generate the required long-term evidence?

Sources

1